(E)-1-(2,5-dimethylthiophen-3-yl)ethanone oxime | 65867-53-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻吩类
• 英文名称: (E)-1-(2,5-dimethylthiophen-3-yl)ethanone oxime
• 英文别名: 1-(2,5-dimethyl-[3]thienyl)-ethanone oxime；1-(2,5-Dimethyl-[3]thienyl)-aethanon-oxim；(NE)-N-[1-(2,5-dimethylthiophen-3-yl)ethylidene]hydroxylamine
• CAS: 65867-53-0
• 化学式: C₈H₁₁NOS
• 分子量: 169.247
• InChiKey: SBTUQKDDLZOUJO-RMKNXTFCSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  60.8
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (E)-1-(2,5-dimethylthiophen-3-yl)ethanone oxime 在 盐酸 、 吡啶硼烷 作用下， 生成 1-(2,5-dimethylthien-3-yl)ethylhydroxylamine
  参考文献：
  名称：

  Structure−Activity Relationships of N-Hydroxyurea 5-Lipoxygenase Inhibitors

  摘要：

  The discovery of second generation N-hydroxyurea 5-lipoxygenase inhibitors was accomplished through the development of a broad structure-activity relationship (SAR) study. This study identified requirements for improving potency and also extending duration by limiting metabolism. Potency could be maintained by the incorporation of heterocyclic templates substituted with selected lipophilic substituents. Duration of inhibition after oral administration was optimized by identification of structural features in the proximity of the N-hydroxyurea which correlated to low in vitro glucuronidation rates. Furthermore, the rate of in vitro glucuronidation was shown to be stereoselective for certain analogs. (R)-N-[3-[5-(4-Fluorophenoxy)-2-furyl]-1-methyl-2-propynyl]-N-hy- droxyurea (17c) was identified and selected for clinical development.

  DOI：

  10.1021/jm9700474
• 作为产物：
  描述：

  2,5-二甲基噻吩 在 磷酸 、 羟胺 、 苯 作用下， 生成 (E)-1-(2,5-dimethylthiophen-3-yl)ethanone oxime
  参考文献：
  名称：

  Acylation Studies in the Thiophene and Furan Series.^1a VIII. Mixed Melting Points of Some Homologous Acetylmethylthiophene Derivatives

  摘要：

  DOI：

  10.1021/ja01152a525

文献信息

• Highly Enantioselective Borane Reduction of Heteroaryl and Heterocyclic Ketoxime Ethers Catalyzed by Novel Spiroborate Ester Derived from Diphenylvalinol: Application to the Synthesis of Nicotine Analogues
  作者：Kun Huang、Francisco G. Merced、Margarita Ortiz-Marciales、Héctor J. Meléndez、Wildeliz Correa、Melvin De Jesús

  DOI：10.1021/jo800204n

  日期：2008.6.1

  An asymmetric synthesis for the preparation of nonracemic amines bearing heterocyclic and heteroaromatic rings is described. A variety of important enantiopure thionyl and arylalkyl primary amines were afforded by the borane-mediated enantioselective reduction of O-benzyl ketoximes using 10% of catalyst 10 derived from (S)-diphenylvalinol and ethylene glycol with excellent enantioselectivity, in up

  描述了制备带有杂环和杂芳环的非外消旋胺的不对称合成。使用 10%衍生自 ( S )-二苯基缬氨醇和乙二醇的催化剂10 ，通过硼烷介导的对映选择性还原O-苄基酮肟，得到各种重要的对映纯亚硫酰基和芳烷基伯胺，具有优异的对映选择性，高达 99% ee 。首次不对称还原 3- 和 4-吡啶基衍生的O-苄基酮肟醚的最佳条件是在 10 °C 下在二恶烷中使用 30% 的催化负载量实现的。( S ) -N-乙基降烟碱 ( 3 ) 也由 TIPS 保护的 ( S )-2-氨基-2-吡啶乙醇在 97% ee 中成功合成。
• Chabrier et al., Bulletin de la Societe Chimique de France, 1946, vol. <5>, p. 332,337
  作者：Chabrier et al.

  DOI：——

  日期：——
• Gol'dfarb et al., Izvestiya Akademii Nauk SSSR, Seriya Khimicheskaya, 1956, p. 340,348; engl. Ausg. S. 327, 333
  作者：Gol'dfarb et al.

  DOI：——

  日期：——
• METH-COHN O.; NARINE B., SYNTHESIS, 1980, NO 2, 133-135
  作者：METH-COHN O.、 NARINE B.

  DOI：——

  日期：——
• Structure−Activity Relationships of <i>N</i>-Hydroxyurea 5-Lipoxygenase Inhibitors
  作者：Andrew O. Stewart、Pramila A. Bhatia、Jonathan G. Martin、James B. Summers、Karen E. Rodriques、Michael B. Martin、James H. Holms、Jimmie L. Moore、Richard A. Craig、Teodozyj Kolasa、James D. Ratajczyk、Hormoz Mazdiyasni、Francis A. J. Kerdesky、Shari L. DeNinno、Robert G. Maki、Jennifer B. Bouska、Patrick R. Young、Carmine Lanni、Randy L. Bell、George W. Carter、Clint D. W. Brooks

  DOI：10.1021/jm9700474

  日期：1997.6.1

  The discovery of second generation N-hydroxyurea 5-lipoxygenase inhibitors was accomplished through the development of a broad structure-activity relationship (SAR) study. This study identified requirements for improving potency and also extending duration by limiting metabolism. Potency could be maintained by the incorporation of heterocyclic templates substituted with selected lipophilic substituents. Duration of inhibition after oral administration was optimized by identification of structural features in the proximity of the N-hydroxyurea which correlated to low in vitro glucuronidation rates. Furthermore, the rate of in vitro glucuronidation was shown to be stereoselective for certain analogs. (R)-N-[3-[5-(4-Fluorophenoxy)-2-furyl]-1-methyl-2-propynyl]-N-hy- droxyurea (17c) was identified and selected for clinical development.